期刊文献+

尼达尼布的合成工艺改进

Research on improvement on the synthesis process of nintedanib
下载PDF
导出
摘要 文章以2-氧化吲哚-6-甲酸甲酯、原苯甲酸三乙酯和醋酐为起始原料反应得到关键中间体:(E)-1-乙酰基-3-(乙氧基-苯基-甲烯基)-2-氧-2,3-二氢-1H-吲哚-6-甲酸甲酯(4),再与另一起始原料N-(4-氨基苯基)-N-甲基-2-(4-甲基哌嗪-1-基)乙酰胺(3)缩合得尼达尼布,纯度99.8%,总收率62.7%。 In this paper,the key intermediate is prepared by the reaction of 2-oxidation of methyl-6-methyl formate,triethyl benzoate and vinegar as the starting material.(E)-1-acetylgroup-3-(ethoxy-phenyl-methenyl)-2-oxo-2,3-dihydro-1H-indole-6-methyl formate methyl ester(4),and then condensed with another starting material,N-(4-aminophenyl)-N-methyl-2-(4-methylpiperazin-1-yl)acetamide(3),forming nintedanid.The purity is 99.8%and the total yield is 62.7%.
作者 杨怡 刘巧云 赵金亮 王菲 Yang Yi;Liu Qiaoyun;Zhao Jinliang;Wang Fei(Changzhou Vocational Institute of Engineering,Changzhou 213164,China;Changzhou Jiade Pharaceutical Technology Co.,Ltd.,Changzhou 213164,China)
出处 《江苏科技信息》 2019年第26期63-66,共4页 Jiangsu Science and Technology Information
基金 2017年江苏省大学生创新创业训练计划项目 项目名称:特发性肺纤维化Ⅲ类新药尼达尼布关键中间体的研发
关键词 尼达尼布 特发性肺纤维化 合成 nintedanib idiopathic pulmonary fibrosis synthesis
  • 相关文献

参考文献4

二级参考文献63

  • 1Woodcock H V, Molyneaux P L, Maher T M. Reduc- ing lung function decline in patients with idiopathic pulmonary fibrosis : Potential of nintedanib [ J ]. Drug design,development and therapy ,2013,7:503.
  • 2Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis [ J ]. European Respira-tory Journal,2010,35 (4) :821 - 829.
  • 3Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fi- brosis[ J]. New England Journal of Medicine, 2011, 365(12) : 1079 - 1087.
  • 4Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of Nintedanib in idiopathic pulmonary fibro- sis[ J ]. New England Journal of Medicine, 2014,370 (22) :2071 - 82.
  • 5US FDA. FDA approves Ofev to treat idiopathic pul- monary fibrosis [ EB/OL]. [ 2014-10-15 ]. http:// www. fda. gov/newsevents/newsroom/pressannounce- ments/ucm418994, htm.
  • 6US FDA. Ofev(nintedanib) :US prescribing information [ EB/OL]. [ 2014-10-28 ]. http://www, accessdata. fda. gov/drugsaffda _ docs/label/2014/205832sOOOlbl. pdf.
  • 7European Medicines Agency. Summary of opinion : Var- gatef(Nintedanib) [ EB/OL]. [ 2014-10-28 ]. http :// www. ema. europa, eu/docs/en GB/document_library/ Summary_of_opinion - Initial_authorisation/human/ 002569/WC500173607. pdf.
  • 8Roth G J, Heckel A, Colbatzky F, et al. Design,syn- thesis,and evaluation of indolinones as triple angioki- nase inhibitors and the discovery of a highly specific 6- methoxycarbonyl-substituted indolinone ( BIBF 1120 ) [ J ]. Journal of medicinal chemistry, 2009,52 ( 14 ) : 4466 - 4480.
  • 9Wolfgang, Dirk, Christian, et al. Intedanib salts and solid state forms thereof cross reference to related ap- plication[ P]. WO 2012/68441 A2.
  • 10Miller K M, Huang W S, Jamison T F. Catalytic asymmetric reductive coupling of alkynes and alde- hydes: Enantioselective synthesis of allylic alcohols and a-hydroxy ketones [ J ]. Journal of the American Chemical Society,2003,12.5 (12) :3442 - 3443.

共引文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部